Superworth

Perspective Therapeutics price to sales ratio CATX

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
126×
May 2024
10-year median
5.3×
10-year range
2.6× to 130×
Peer median
1.4×

Perspective Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2024, at 126×.

On the days it had one over the last ten years, its median was 5.3×, from 2.6× in Oct 2020 to 130× in May 2024.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2024126×16.4×130×
202313.8×3.8×24.6×
20223.5×3.0×5.5×
20215.4×5.4×23.7×
20204.0×2.6×7.6×
20195.1×2.8×5.5×
20183.4×3.3×5.9×
20174.5×4.5×8.3×
20167.0×6.3×12.8×
201510.7×10.7×24.0×
201419.9×4.3×38.3×
20134.2×3.6×6.0×
20125.3×2.8×5.7×

Against its peers

Companies in Drug Manufacturers - General nearest Perspective Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
CATXPerspective Therapeuticsn/m
NATRNatures Sunshine Products0.4×
LFVNLifevantage0.4×
ARVNArvinas1.5×
SPROSpero Therapeutics1.4×
PBYIPuma Biotechnology2.5×
IRWDIronwood Pharmaceuticals1.5×
ZVRAZevra Therapeutics4.3×
CRMDCorMedix1.3×
ATNMActinium Pharmaceuticalsn/m
COLLCollegium Pharmaceutical0.9×
Peer median1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Perspective Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.